Current management of patients with chronic myelomonocytic leukemia
Ana Alfonso1, Guillermo Montalban-Bravo, Guillermo Garcia-Manero
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Insights
Chronic myelomonocytic leukemia (CMML) management is evolving. Incorporating mutation data improves prognostic models, but new therapies are needed to enhance patient outcomes beyond current standards.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder.
- Characterized by peripheral blood monocytosis and bone marrow dysplasia/neoplasia.
- Exhibits heterogeneous clinical behavior, ranging from indolent to aggressive disease courses.
Purpose of the Study:
- To review current management strategies for CMML.
- To explore future therapeutic perspectives for CMML patients.
- To discuss the role of prognostic factors in guiding treatment decisions.
Main Methods:
- Review of current literature on CMML management.
- Analysis of clinical, cytogenetic, and mutational prognostic features.
- Evaluation of existing and emerging therapeutic options.
Main Results:
- Prognostic models are enhanced by incorporating mutational data, especially ASXL1 mutations.
- Allogeneic stem cell transplantation offers potential cure but is limited to a subset of patients.
- Hypomethylating agents (5-azacitidine, decitabine) are current therapeutic mainstays.
Conclusions:
- Accurate prognostication in CMML is improving with integrated molecular data.
- Novel therapeutic strategies are essential to improve outcomes for CMML patients.
- Further research is needed to develop more effective treatments for this challenging leukemia.
Purpose Of Review:
The present review will focus on the current management of patients with chronic myelomonocytic leukemia (CMML) as well as in future therapeutic perspectives.
Recent Findings:
CMML is a clonal hematopoietic stem cell disorder characterized by peripheral blood monocytosis and myelodysplastic and myeloproliferative alterations in the bone marrow. Clinical behavior of the disease can be heterogeneous, with some patients having an indolent form of the disease, whereas others experience an aggressive course with decreased survival and eventual transformation to leukemia. Multiple studies have helped define the clinical, cytogenetic and mutational prognostic features of the disease. In addition, several prognostic scoring systems have been developed for patients with CMML. Incorporation of mutation data, particularly presence of frameshift and nonsense ASXL1 mutations, into these models seems to be allowing to further improve our ability to predict patient outcomes.
Summary:
Prognosis of patients with CMML is heterogeneous. Incorporation of mutational data into current clinical prognostic models has allowed to improve our ability to predict patient outcomes. Allogeneic stem cell transplantation remains the only potentially curative treatment for patients with CMML but is only an option for a subset of patients. For this reason, hypomethylating agents such as 5-azacitidine and decitabine have become the backbone of current therapy for patients with CMML, but new therapeutic strategies are required to improve their outcomes.
Related Concept Videos
01:22Myocarditis IV: Nursing Management
01:18Chronic Kidney Disease IV: Nursing Management
01:15Differentiation of Common Myeloid Progenitor Cells